AURORA CANNABIS INC (ACB) Form 6-K — Nov 5, 2026
Aurora Cannabis reported fiscal Q2 2027 results while confirming that Organigram Global will acquire all outstanding Aurora shares under an Arrangement Agreement announced November 3, 2026. Aurora posted net revenue of C$86.0 million, up 9% year-over-year, driven by record international medical cannabis revenue of C$61.4 million (+44% YoY), though Canadian medical revenue fell 24% due to changes in the federal reimbursement program. The company held C$133.0 million in cash with no debt. Aurora shareholders will receive C$7.80 in cash, 5.8626 Organigram shares, or a mixed C$3.75 cash plus 3.0431 Organigram shares per Aurora share, subject to proration.
Key figures
- Revenue
- C$86.0 million
- Net Income
- C$-21.1 million (net loss from continuing operations)
- Revenue Yoy
- 9%
- Cash Position
- C$133.0 million cash, equivalents and short-term investments, no debt
- Deal Value Usd
- C$7.80 per share cash alternative
- Expected close
- January 2027
- Free cash flow
- C$-17.5 million (improved C$22.4 million YoY)
- Adjusted ebitda
- C$14.0 million (vs C$15.4M prior year)
- Adjusted net income
- C$3.1 million (vs C$12.0M prior year)
- Mixed consideration
- C$3.75 cash plus 3.0431 Organigram shares
- Canadian medical revenue
- C$21.2 million (-24% YoY)
- Medical cannabis revenue
- C$82.5 million (+17% YoY)
- International medical revenue
- C$61.4 million (44% YoY increase)
- Organigram share exchange ratio
- 5.8626 shares per Aurora share
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.